Generic Injectables Market Size & Share | Global Trends 2021, 28
仿制注射剂市场规模预计将从 2021 年的 747.4 亿美元增至 2028 年的 1506.5 亿美元;预计 2021 年至 2028 年的复合年增长率为 10.5%。injectables market is projected to reach US$ 150.65 billion by 2028 from US$ 74.74 billion in 2021; it is expected to register a CAGR of 10.5% from 2021 to 2028.
仿制注射剂是其品牌注射剂的生物等效剂,不受专利保护。它们与创新药物一样安全有效,因为它们具有相似的活性成分、剂量、强度、品质、形式等。该报告提供了对仿制注射剂市场
的见解和深入分析,强调了市场趋势、技术进步和市场动态等各种参数;它还提供了主要市场参与者的竞争格局分析以及 COVID-19 大流行对所有主要地区市场的影响。COVID-10 大流行扰乱了世界各国的社会经济状况。根据世界卫生组织最近的统计数据,美国是世界上受疫情影响最严重的国家,病例数也最多。大量的 COVID 病例对美国经济产生了负面影响,并进而影响到北美经济。该地区各个行业的整体商业活动和增长都有所下降。
定制研究以满足您的需求
我们可以优化和定制标准产品无法满足的分析和范围。这种灵活性将帮助您获得业务规划和决策所需的准确信息。
通用注射剂市场:
Generic Injectables Market: Strategic Insights
Generic Injectables Market
-
CAGR (2021 - 2028)
10.5%
-
Market Size 2021
US$ 74.74 Billion
-
Market Size 2028
US$ 150.65 Billion
Market Dynamics
GROWTH DRIVERS
- XXXXXXX
- XXXXXXX
- XXXXXXX
FUTURE TRENDS
- XXXXXXX
- XXXXXXX
- XXXXXXX
OPPORTUNITIES
- XXXXXXX
- XXXXXXX
- XXXXXXX
Key Players
- Astrazeneca
- Baxter International Inc
- Biocon
- Fresenius SE Co KGaA
- GlaxoSmithKline Plc
- Hikma Pharmaceuticals
- Johnson Johnson Services Inc
- Lupin Ltd
- Merck Co Inc
Regional Overview
- 北美(美国、加拿大、墨西哥)
- 欧洲(英国、德国、法国、俄罗斯、意大利、欧洲其他地区)
- 亚太地区(中国、印度、日本、澳大利亚、亚太地区其他地区)
- 南美洲和中美洲(巴西、阿根廷、南美洲和中美洲其他地区)
- 中东和非洲(南非、沙特阿拉伯、阿联酋、中东和非洲其他地区)
Market Segmentation
产品类型(大分子注射剂和小分子注射剂)
容器类型(小瓶、预混料、预充式注射器、安瓿瓶及其他)
应用(肿瘤学、传染病、心脏病学、糖尿病、免疫学等)
给药途径(静脉注射、肌肉注射、皮下注射及其他)
Generic Injectables Market: Strategic Insights
-
CAGR (2021 - 2028)10.5% -
Market Size 2021
US$ 74.74 Billion -
Market Size 2028
US$ 150.65 Billion
Market Dynamics
- XXXXXXX
- XXXXXXX
- XXXXXXX
- XXXXXXX
- XXXXXXX
- XXXXXXX
- XXXXXXX
- XXXXXXX
- XXXXXXX
Key Players
- Astrazeneca
- Baxter International Inc
- Biocon
- Fresenius SE Co KGaA
- GlaxoSmithKline Plc
- Hikma Pharmaceuticals
- Johnson Johnson Services Inc
- Lupin Ltd
- Merck Co Inc
Regional Overview
- 北美(美国、加拿大、墨西哥)
- 欧洲(英国、德国、法国、俄罗斯、意大利、欧洲其他地区)
- 亚太地区(中国、印度、日本、澳大利亚、亚太地区其他地区)
- 南美洲和中美洲(巴西、阿根廷、南美洲和中美洲其他地区)
- 中东和非洲(南非、沙特阿拉伯、阿联酋、中东和非洲其他地区)
Market Segmentation
复合年增长率(2021 - 2028 年)10.5%- 2021 年市场规模
747.4 亿美元 - 2028 年市场规模
1506.5 亿美元
市场动态
- 財政部
- 財政部
- 財政部
- 財政部
- 財政部
- 財政部
- 財政部
- 財政部
- 財政部
关键人物;主力;重要一员
- 阿斯利康
- 百特国际有限公司
- 比奥康
- 费森尤斯集团
- 葛兰素史克公司
- 希克玛制药公司
- 强生服务公司
- 鲁宾有限公司
- 默克公司
区域概况
- 北美
- 欧洲
- 亚太
- 南美洲和中美洲
- 中东和非洲
市场细分
- 大分子注射剂和小分子注射剂
- 西林瓶
- 预混料
- 预充式注射器
- 安瓿
- 其他的
- 肿瘤学
- 传染性疾病
- 心脏病学
- 糖尿病
- 免疫学
- 其他的
- 静脉
- 肌肉注射
- 皮下
- 其他的
- 示例 PDF 通过定性和定量分析展示了内容结构和信息的性质。
然而,在疫情最严重的时候,用于治疗患者的抗病毒药物瑞德西韦的需求异常旺盛。因此,仿制注射剂市场的制造商现在已经为未来做好了准备,他们专注于保持足够的库存,以确保供应链运营不受任何类型的漏洞影响。例如,吉利德科学和其他大型制药公司已大幅降低了其瑞德西韦仿制药的价格。各公司正在利用政府计划和 BFSI 行业提供的融资计划来精简其运营。2020 年 5 月,美国政府与一群美国仿制药制造商达成了一项价值 8.12 亿美元的协议,目的是在全球 COVID-19 大流行期间加强该国的药品供应。
此外,这场大流行给全球制药业带来了压力,中断和延迟了各种关键药物的供应。许多市场参与者立即采取行动来拯救疫情。例如,2021 年 1 月,Civica Rx 与新成立的 Phlow Corp. 合作,努力支持美国的药品生产,并向抗击疫情的医院供应关键药物。Civica 投资 1.245 亿美元在弗吉尼亚州彼得斯堡建造了一座无菌注射剂制造工厂,该工厂去年因获得一份生产 COVID-19 相关药物的政府大合同而声名鹊起。
根据地区,仿制注射剂市场分为北美、欧洲、亚太地区、中东和非洲以及南美洲和中美洲。
市场洞察
对平价药品的高需求推动仿制注射剂市场
由于在分子研发上投入大量资金,创新药价格昂贵;这些药物对于发展中国家的大部分人口来说尤其难以负担。然而,仿制药价格实惠,并能提供更大的医疗保健机会。据可及药物协会 (AAM) 发布,仿制药的平均主要自付费用(保险计划规定的金额)为 6.06 美元,品牌药为 40.30 美元。这一事实表明仿制药价格至少下降了约 7%。根据美国退休人员协会 (AARP) 的数据,品牌药价格继续以比通货膨胀率高 100 倍的速度上涨。此外,正如美国食品药品监督管理局所提到的,美国 9/10 的处方都是仿制药。此外,仿制药的平均制造商价格 (AMP) 比品牌药的 AMP 低约 39%。例如,根据可及药物协会 (AAM) 公布的数据,93% 的仿制药处方价格为 20 美元或更低。上述事实推动了仿制药注射剂的需求和供应,从而推动更多参与者进入仿制药注射剂市场。
此外,仿制药注射剂的低价有助于更好地治疗慢性病。根据世界卫生组织 (WHO) 的数据,2021 年全球约有 4.22 亿人患有糖尿病。仿制药注射剂(如胰岛素注射剂)可为此类疾病提供即时解决方案,同时确保发展中国家能够负担得起治疗费用。
基于产品类型的洞察
根据产品类型,仿制注射剂市场分为大分子注射剂和小分子注射剂。2021 年,大分子注射剂细分市场占据了更大的市场份额。该细分市场的市场地位归功于医疗保健领域对生物制剂的采用激增,以及单克隆抗体和抗体-药物偶联物 (ADC) 在药物开发中的进展。
基于容器类型的洞察
根据容器类型,仿制注射剂市场分为小瓶、预混剂、预充式注射器、安瓿瓶等。小瓶部分很可能在 2021 年占据市场主导地位。
基于应用的洞察
根据应用,仿制注射剂市场分为肿瘤学、传染病、心脏病学、糖尿病、免疫学等。肿瘤学领域很可能在 2021 年占据最大的市场份额。预计癌症发病率的上升和药物上市数量的增加将推动肿瘤学市场领域的增长。
通用注射剂市场报告范围
报告属性 | 细节 |
---|---|
2021 年市场规模 | 747.4亿美元 |
2028 年市场规模 | 1506.5亿美元 |
全球复合年增长率(2021 - 2028) | 10.5% |
历史数据 | 2019-2020 |
预测期 | 2022-2028 |
涵盖的领域 | 按产品类型
|
覆盖地区和国家 | 北美
|
市场领导者和主要公司简介 |
|
- 示例 PDF 通过定性和定量分析展示了内容结构和信息的性质。
基于给药途径的见解
根据给药途径,仿制注射剂市场分为静脉注射、肌肉注射、皮下注射和其他注射。静脉注射部分在 2021 年占据了最大的市场份额。
仿制注射剂市场参与者采用产品发布和扩张等有机策略来扩大其全球足迹和产品组合。
按地理位置
北美
- 我们
- 加拿大
- 墨西哥
欧洲
- 法国
- 德国
- 意大利
- 英国
- 西班牙
- 欧洲其他地区
亚太地区 (APAC)
- 中国
- 印度
- 韩国
- 日本
- 澳大利亚
- 亚太地区其他地区
中东和非洲 (MEA)
- 南非
- 沙特阿拉伯
- 阿联酋
- MEA 其他地区
南美洲和中美洲(SCAM)
- 巴西
- 阿根廷
- 其余的骗局
公司简介
- 阿斯利康
- 百特国际有限公司
- 比奥康
- 费森尤斯集团
- 葛兰素史克公司
- 希克玛制药公司
- 强生服务公司
- 鲁宾有限公司
- 默克公司
- 迈兰公司
- 辉瑞公司
Generic Injectables Market Report Scope
Report Attribute | Details |
---|---|
Market size in | US$ 74.74 Billion |
Market Size by | US$ 150.65 Billion |
Global CAGR | 10.5% |
Historical Data | 2019-2020 |
Forecast period | 2022-2028 |
Segments Covered |
By 产品类型(大分子注射剂和小分子注射剂) |
Regions and Countries Covered |
北美(美国、加拿大、墨西哥)
|
Market leaders and key company profiles |
|
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
Global generic injectables market is segmented by region into North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America. In North America, the U.S. is the largest market for generic injectables market. The US is estimated to hold the largest share in the generic injectables market during the forecast period. The presence of top players and favorable regulations related to product approvals coupled with commercializing new products are the contributing factors for the regional growth. Additionally, the increasing number of technological advancements is the key factor responsible for the Asia-Pacific regional growth for generic injectables accounting fastest growth of the region during the coming years.
The oncology segment dominated the global generic injectables market and accounted for the largest revenue of 21.62 Bn in 2021.
Astrazeneca, Baxter International, Inc., Biocon, Fresenius SE & Co., KGaA, GlaxoSmithKline Plc, Hikma Pharmaceuticals, Johnson & Johnson Services, Inc., Lupin, Ltd., Merck & Co., Inc., Mylan N.V., Pfizer, Inc. are among the leading companies operating in the global generic injectables market
Generic Injectables are safe and effective innovator bio-equivalent drugs of their branded counterparts which are not protected by drug patents. They have a similar ingredient, dosage, strength, quality, form, etc.
High demand for affordable drugs is one of the most significant factors responsible for the overall market growth.
Based on product type, large molecule injectables took the forefront leaders in the worldwide market by accounting largest share in 2020 and is expected to continue to do so till the forecast period.
The List of Companies - Generic Injectables Market
- Astrazeneca
- Baxter International, Inc.
- Biocon
- Fresenius SE & Co. KGaA
- GlaxoSmithKline Plc
- Hikma Pharmaceuticals
- Johnson & Johnson Services, Inc.
- Lupin, Ltd.
- Merck & Co., Inc.
- Mylan N.V.
- Pfizer, Inc.
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.